Mercury Laboratories Assigns Additional VP Role to Chief Operating Officer

Mercury Laboratories Limited has assigned an additional role of Vice President-Marketing Sales to Saurabh Mittal, who serves as Chief Operating Officer, effective November 17, 2025. The appointment involves a senior management personnel with over 15 years of corporate experience in marketing, business development, and system processes across established and start-up organizations.

Mercury Laboratories Reports 69% Jump in Quarterly Net Profit to Rs 164.33 Lakhs

Mercury Laboratories Limited announced its unaudited financial results for the quarter and half year ended September 30, 2025. The pharmaceutical company reported a net profit after tax of Rs 164.33 lakhs for the quarter, compared to Rs 96.76 lakhs in the previous quarter, representing a significant increase. Revenue from operations for the quarter stood at Rs 1,900.86 lakhs, up from Rs 1,813.54 lakhs in the previous quarter. For the half year period, net profit reached Rs 261.09 lakhs with revenue from operations at Rs 3,714.40 lakhs. The company's total comprehensive income for the quarter was Rs 164.00 lakhs. Basic earnings per share for the quarter was Rs 13.69 compared to Rs 8.06 in the previous quarter. The Board of Directors approved these results at their meeting held on November 11, 2025. The company operates in a single segment of pharmaceutical products and has paid-up equity share capital of Rs 120.00 lakhs with face value of Rs 10 per share.

Mercury Laboratories Appoints Seema Salvi as Head of Injectable Production Department

Mercury Laboratories Limited appointed Ms. Seema Salvi as Head of the Injectable Production Department effective November 04, 2025. Salvi, aged 49, holds a Bachelor's degree in Pharmacy and brings over 26 years of experience in injection production. She was previously associated with Harson Laboratories India Pvt. Ltd. and Crescent Labs Pvt Ltd. The appointment is for full-time employment as part of the company's senior management personnel changes.

Mercury Laboratories Shareholders Approve All Resolutions at 44th AGM Including ₹3.50 Dividend

Mercury Laboratories Limited held its 44th Annual General Meeting on August 13, 2025, via video conferencing with 1,405 shareholders on record. All nine resolutions were approved with overwhelming support, including adoption of audited financial statements for the year ended March 31, 2025, and declaration of ₹3.50 dividend per equity share of ₹10 each. Key appointments approved include re-appointment of Ms. Janki R Shah as Non-Executive Non-Independent Director, approval of her remuneration exceeding 50% of total non-executive director remuneration, re-appointment of Mr. Rajendra R Shah as Managing Director effective April 1, 2026, and appointment of Mr. Sanjay Patel as Independent Director. Shareholders also approved remuneration for Mr. Paresh Mistry as Non-Executive Director, ratified cost auditor remuneration for 2025-26, and appointed Dholakia & Associates LLP as secretarial auditors. The meeting saw participation from 41 shareholders (9 promoters, 32 public) through video conferencing, with voting conducted through remote e-voting and e-voting during the AGM.